Evidence map›Paper›PMID 41390880›Full record

ArticleNPJ precision oncology2025

Plasma cell-free DNA methylation-based prognosis in metastatic castrate-resistant prostate cancer.

Jodie Wong, Yijun Tian, Manishkumar S Patel, Kapil Avasthi, Claire Hanson, Matt Larsen, Enos Ampaw, Rebekah Gutowski, Muhammad Z H Fadlullah, Joseph Finkelstein and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Jodie WongDepartment of Tumor Microenvironment & Metastasis, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Yijun TianDepartment of Tumor Microenvironment & Metastasis, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Manishkumar S PatelDepartment of Tumor Microenvironment & Metastasis, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Kapil AvasthiDepartment of Tumor Microenvironment & Metastasis, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Claire HansonDivision of Oncology, Department of Medicine, University of Utah, Huntsman Cancer Institute, Salt Lake City, UT, USA.
Matt LarsenDivision of Oncology, Department of Medicine, University of Utah, Huntsman Cancer Institute, Salt Lake City, UT, USA.
Enos AmpawDivision of Oncology, Department of Medicine, University of Utah, Huntsman Cancer Institute, Salt Lake City, UT, USA.
Rebekah GutowskiDivision of Oncology, Department of Medicine, University of Utah, Huntsman Cancer Institute, Salt Lake City, UT, USA.
Muhammad Z H FadlullahDepartment of Oncological Sciences, University of Utah, Huntsman Cancer Institute, Salt Lake City, UT, USA.
Joseph FinkelsteinDepartment of Biomedical Informatics, University of Utah, Huntsman Cancer Institute, Salt Lake City, UT, USA.
Aik Choon TanDepartment of Oncological Sciences, University of Utah, Huntsman Cancer Institute, Salt Lake City, UT, USA.
Jong ParkDepartment of Cancer Epidemiology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Brandon J ManleyDepartment of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Chiang-Ching HuangZilber College of Public Health, University of Wisconsin, Milwaukee, WI, USA.
Manish KohliDivision of Oncology, Department of Medicine, University of Utah, Huntsman Cancer Institute, Salt Lake City, UT, USA. Manish.Kohli@hci.utah.edu.
Liang WangDepartment of Tumor Microenvironment & Metastasis, H. Lee Moffitt Cancer Center, Tampa, FL, USA. Liang.Wang@Moffitt.org.

Funding

Cell free nucleic acid-based biomarkers in advanced prostate cancerR01CA212097 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI KOHLI, MANISH, WANG, LIANG · 2017 to 2022
$3.1M
NCI NIH HHS R01 CA212097NIH HHS R01CA212097
6 · The paper itself

Abstract

Molecular prognostication in metastatic castration-resistant prostate cancer (mCRPC) remains a challenge due to the lack of validated biomarkers. This study developed a plasma cell-free DNA (cfDNA) methylation-based prognostic model in mCRPC. Targeted cfDNA methylation sequencing in 96 prostate cancer patients across different states of cancer progression revealed 77 methylation haplotype blocks (MHBs) differentially methylated from organ-confined prostate cancer to mCRPC states. Among these 77 MHBs, the top 20 MHBs were associated with mCRPC overall survival and most MHB methylation levels positively correlated with predicted circulating tumor DNA (ctDNA) fraction. By integrating the MHB-based risk score with currently available prognostic clinical variables and ctDNA fraction, a prognostic nomogram was developed which showed high predictive performance for mCRPC survival (AUC = 0.99 for 6 months, AUC = 0.84 for 1 year, and AUC = 0.82 for 2 years). These findings demonstrate potential of cfDNA methylation as a molecular biology-driven biomarker for mCRPC prognosis.

Identifiers

PMID41390880
PMCPMC12816654

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.